This Week in Rheumatology — Jun 24, 2026

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning emerging cellular and molecular targets in systemic autoimmune diseases, real-world evidence and imaging in inflammatory arthritis, and system-level insights into care pathways and drug regulation. Let's dive in.

Our first clinical theme explores the frontiers of refractory systemic autoimmune diseases, examining novel cellular therapies, underlying pathogenic pathways, and critical clinical predictors of severe complications. We begin with a highly anticipated multicentre case series published in Annals of the Rheumatic Diseases that evaluated the safety and efficacy of teclistamab, a T-cell-redirecting bispecific antibody targeting B-cell maturation antigen, in patients with severe, treatment-refractory autoimmune diseases [9]. This retrospective study analyzed eighteen patients across five European centres who had received a median of five prior therapies. The cohort included ten patients with systemic sclerosis, four with idiopathic inflammatory myopathies, two with systemic lupus erythematosus, one with undifferentiated connective tissue disease, and one with immunoglobulin G4-related disease. Over a median follow-up of five point one months, teclistamab demonstrated substantial clinical activity, with eleven patients, or sixty-one percent, achieving a major clinical response, and another four patients achieving minimal-to-moderate responses, even as they discontinued baseline immunosuppressive therapy. However, this potent efficacy was accompanied by significant, clinically relevant safety concerns. All eighteen patients developed severe hypogammaglobulinaemia, and twenty-eight percent experienced severe infections. Additionally, twelve patients experienced a total of twenty-two cytokine release syndrome episodes, though most were mild-to-moderate. Most concerningly, two patients with advanced systemic sclerosis-associated cardiac involvement died during the study—one due to sudden cardiac death and the other following diffuse alveolar haemorrhage and heart failure. These findings suggest that while teclistamab represents a promising option for inducing treatment-free responses in highly refractory diseases, clinicians must exercise extreme caution, ensuring rigorous patient selection that excludes those with advanced cardiac involvement, alongside vigilant post-infusion monitoring.

This therapeutic advance is closely tied to our evolving understanding of the molecular pathways driving these diseases, such as endosomal nucleic acid sensing. Writing in Nature Reviews Rheumatology, researchers highlight how Toll-like receptor 7, or TLR7, has emerged as a key pathogenic driver in systemic lupus erythematosus [7]. Genetic studies have identified that gain-of-function mutations in TLR7 and its chaperone protein, UNC93B1, can cause monogenic, childhood-onset lupus, while rare variants in regulatory proteins further contribute to disease susceptibility by increasing receptor affinity for endogenous ligands. This pathway leads to B-cell tolerance breakdown, autoantibody production, and robust type one interferon secretion. While advanced therapies like chimeric antigen receptor T-cell therapies and anifrolumab offer therapeutic options, they are limited by high costs and a lack of oral administration routes. In this light, oral dual TLR7 and TLR8 antagonists represent a promising alternative. Phase two trials of these oral agents have shown durable suppression of the interferon signature in all treated patients, proving that these receptors actively drive this signature in lupus. While the primary endpoint of a dose-response effect was only met in patients with cutaneous lupus, the treatment demonstrated notable clinical benefit in both systemic and cutaneous disease, suggesting these oral antagonists could significantly reshape the future treatment landscape.

Further elucidating the cellular mechanisms of fibrotic disease, a study published in Arthritis and Rheumatology investigated how mitochondrial dysfunction drives skin fibrosis in systemic sclerosis [3]. By analyzing plasma from fifty patients with systemic sclerosis and twenty healthy controls, researchers found that circulating mitochondrial DNA levels were significantly elevated in patients with systemic sclerosis. Crucially, these circulating mitochondrial DNA levels negatively correlated with lung function, as measured by forced vital capacity percentage, and positively correlated with skin thickness, measured by the modified Rodnan skin score, as well as levels of interleukin-six and transforming growth factor-beta. In primary dermal fibroblasts from patients with diffuse cutaneous systemic sclerosis, the researchers observed abnormal mitochondrial morphology and function. Specifically, increased expression of the mitochondrial calcium uniporter and voltage-dependent anion channel one promoted mitochondrial calcium overload. This overload triggered the opening of the mitochondrial permeability transition pore and channel oligomerization, leading to the leakage of mitochondrial DNA into the cytosol. This cytosolic accumulation subsequently activated the cyclic GMP-AMP synthase-stimulator of interferon genes, or cGAS-STING pathway, driving profibrotic activation. Reassuringly, pharmacological blockade of the mitochondrial pore or the anion channel successfully reduced cytosolic mitochondrial DNA, and treatment with the STING inhibitor H-151 suppressed profibrotic markers in patient fibroblasts and attenuated dermal thickening and collagen deposition in a mouse model. This calcium-mitochondrial DNA-cGAS-STING axis highlights a clear, targetable pathway for future anti-fibrotic therapies.

While understanding these cellular mechanisms is vital for long-term therapeutic development, identifying which patients are at imminent risk of severe complications remains a primary clinical priority. This is particularly true in anti-MDA5 antibody-positive dermatomyositis, which is frequently complicated by rapidly progressive interstitial lung disease. A systematic review and meta-analysis published in Rheumatology investigated predictors of this life-threatening complication across twenty-seven cohorts comprising over twenty-five hundred patients [1]. The investigators identified several key clinical characteristics that predict a higher risk of rapidly progressive interstitial lung disease, including advanced age, male sex, fever, skin ulcers, and arthritis. On laboratory evaluation, patients who progressed to rapid lung disease exhibited significantly elevated levels of C-reactive protein, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, ferritin, erythrocyte sedimentation rate, leukocytes, Krebs von den Lungen-six, cartilage glycoprotein thirty-nine, positive anti-Ro52 antibodies, and high-titre anti-MDA5 antibodies. Conversely, those at risk had significantly lower levels of lymphocytes, albumin, CD3-positive CD4-positive T-cell counts, and a reduced ratio of arterial oxygen tension to fraction of inspired oxygen. Identifying this clinical and biochemical profile can help clinicians risk-stratify patients with anti-MDA5 positive dermatomyositis early, allowing for aggressive, preemptive immunosuppressive therapy before irreversible lung damage occurs.

We now transition to our second clinical theme, which focuses on optimising management strategies, evaluating pain, and utilizing imaging in inflammatory arthritis. We begin with real-world evidence from Canadian and Swiss registries published in Rheumatology, which compared the long-term persistence and effectiveness of the Janus kinase inhibitor upadacitinib against tumor necrosis factor inhibitors in patients with rheumatoid arthritis [2]. Analyzing data from nine hundred ninety patients who initiated treatment between 2020 and 2023, the researchers adjusted for baseline differences using propensity scores. They discovered that patients receiving upadacitinib had a significantly lower risk of discontinuing their treatment than those on tumor necrosis factor inhibitors, representing a roughly forty percent reduction in the risk of discontinuation. This superior drug persistence was observed regardless of whether patients had previously been exposed to advanced biologic therapies. For both treatment groups, the concomitant use of any conventional synthetic disease-modifying antirheumatic drug, and methotrexate specifically, was associated with significantly improved persistence. Interestingly, despite the differences in drug survival, clinical effectiveness was comparable between the two cohorts. Similar proportions of patients achieved low disease activity or remission on the Clinical Disease Activity Index at six months, with seventy point eight percent in the upadacitinib group compared to sixty-one percent in the tumor necrosis factor inhibitor group, and at twelve months, with seventy point five percent versus seventy-five point two percent, respectively. These differences did not reach statistical significance, indicating that while upadacitinib may offer superior long-term persistence, both classes remain highly effective options.

While controlling disease activity is a primary goal, clinicians must also address the common and frustrating clinical challenge of persistent pain in patients who otherwise appear to have well-controlled rheumatoid arthritis. A large, nationwide cohort study from Sweden, published in Annals of the Rheumatic Diseases, examined predictors of unacceptable pain, defined as a visual analogue scale score greater than forty millimetres, in over ten thousand patients with early rheumatoid arthritis [8]. At the two-year follow-up, thirty-three percent of patients continued to experience unacceptable pain, and remarkably, twenty-six percent of patients experienced unacceptable pain despite having low systemic inflammation, defined as a C-reactive protein level below ten milligrams per litre. The researchers identified several baseline predictors of both overall unacceptable pain and unacceptable pain in the setting of low inflammation. These predictors included female sex, worse baseline patient-reported outcomes, lower baseline parameters of systemic inflammation, and a higher ratio of tender to swollen joints. Additionally, smoking, non-European origin, and pre-existing psychiatric or pain-related comorbidities were associated with higher pain levels over time. These findings highlight that pain in rheumatoid arthritis is multifactorial and frequently uncoupled from active joint inflammation. Clinicians should recognize that patients presenting with a high tender-to-swollen joint count ratio and poor patient-reported outcomes at baseline are at elevated risk for persistent pain, necessitating early, multi-modal pain management strategies that extend beyond traditional anti-inflammatory escalations.

When initiating these advanced therapies, ensuring equitable treatment response across diverse patient populations is a critical aspect of quality care. A study from the United Kingdom Juvenile Idiopathic Arthritis Biologics Register, published in Rheumatology, investigated the impact of ethnicity and socioeconomic position on clinical outcomes and drug persistence in over sixteen hundred pediatric patients starting their first tumor necrosis factor inhibitor [10]. The cohort was predominantly female and White, with ten percent of patients from minority ethnic groups and twenty-five percent residing in the most deprived socioeconomic areas. Encouragingly, the study found that juvenile arthritis disease activity scores improved significantly across all ethnic and socioeconomic groups by six months, with no statistically significant differences in the magnitude of improvement. Furthermore, drug persistence at twelve months was sixty-seven percent overall, and the likelihood of treatment discontinuation was similar across all socioeconomic and ethnic demographics. These reassuring findings suggest that once access to biologic therapy is secured, tumor necrosis factor inhibitors provide equitable and highly effective clinical benefits to all children and young people with juvenile idiopathic arthritis, regardless of their background or socioeconomic status.

To optimize the timing and monitoring of these therapies in peripheral spondyloarthritis, objective imaging modalities are increasingly utilized, though their exact role in very early disease remains under investigation. A study published in Arthritis and Rheumatology evaluated the diagnostic performance and treatment responsiveness of ultrasound features in patients with very early peripheral spondyloarthritis, with symptom durations of less than twelve weeks, enrolled in the placebo-controlled CRESPA trial [4]. The researchers performed repeated clinical and ultrasound evaluations of joints and entheses in fifty-four patients. At baseline, synovial hypertrophy was uncommon and did not independently predict clinical joint swelling. In contrast, a Power Doppler signal of grade one or higher and the presence of joint effusion on ultrasound were strong predictors of a clinically swollen joint, increasing the odds of swelling by roughly nine and eight times, respectively. Treatment with the tumor necrosis factor inhibitor golimumab significantly predicted the resolution of these ultrasound features compared to placebo. However, the evaluation of enthesitis revealed a notable mismatch between clinical examination and ultrasound imaging. Forty-five percent of clinically tender entheseal sites showed no ultrasound abnormalities, while nineteen percent of non-tender entheses did. Across all four hundred thirty-two entheses evaluated, only entheseal thickening and a Power Doppler signal of grade one or higher predicted clinical tenderness. While golimumab treatment was highly effective at resolving ultrasound-detected entheseal thickening, hypoechogenicity, and Power Doppler signal, these findings caution clinicians that clinical examination frequently overestimates enthesitis in early disease. This underscores the need for standardized ultrasound scoring systems and validated thresholds to improve diagnostic accuracy and monitor treatment response effectively.

Our final clinical theme shifts focus to the broader context of rheumatology practice, examining how healthcare systems and international regulatory frameworks shape patient care and drug development. A study published in Annals of the Rheumatic Diseases analyzed routinely collected healthcare data to compare referral pathways and the duration of care for musculoskeletal complaints across five European countries [5]. Looking at primary care data from over four million adults and secondary care data from over six hundred thousand rheumatology patients, the researchers found that while primary care presentation rates for musculoskeletal issues were remarkably consistent—with twenty-five to thirty percent of residents visiting a general practitioner annually for these complaints—referral rates to specialist rheumatology care varied widely, ranging from five percent in some countries to thirty-eight percent in others. In countries like the United Kingdom and Sweden, which feature lower referral rates, fewer rheumatologists per capita, and selective triaging systems, a higher proportion of referred patients remained in long-term rheumatology care. Conversely, in countries like the Netherlands, Spain, and Hungary, which employ nonselective triaging and have higher referral rates, forty-six to seventy percent of referred patients were discharged within three months. This demonstrates that healthcare system architecture and triaging mechanisms heavily influence the patient mix and the duration of care in secondary rheumatology clinics, which is an essential consideration when developing international clinical guidelines and referral tools.

On a global scale, differences in regulatory requirements can also impact how quickly new therapies reach patients. A Health Policy paper in The Lancet Rheumatology compared current recommendations from the United States Food and Drug Administration and the European Medicines Agency for clinical trials of new rheumatoid arthritis treatments [6]. While both regulatory bodies align on core principles—such as the use of composite clinical endpoints, validated patient-reported outcomes, the prevention of structural joint damage, and limits on placebo duration—they differ on key study design requirements. The European Medicines Agency favors low disease activity or clinical remission as primary endpoints, typically requires two pivotal phase three trials in distinct patient populations, and generally mandates background methotrexate use. In contrast, the United States Food and Drug Administration offers greater flexibility in primary endpoint selection, allows for a single pivotal trial if supported by strong confirmatory evidence, and places a higher emphasis on early dose-response characterization. Greater alignment and harmonization between these two major regulatory agencies could reduce clinical trial duplication, streamline the interpretation of global data, and ultimately accelerate patient access to novel therapies worldwide.

If you only have time for one paper this week, make it the multicentre case series on teclistamab for treatment-refractory autoimmune diseases published in Annals of the Rheumatic Diseases [9]. This study provides a crucial first look at the immense clinical potential of T-cell-redirecting bispecific therapies in severe connective tissue diseases, while delivering an urgent safety warning regarding severe infections and fatal outcomes in patients with pre-existing cardiac involvement.

Here are the key takeaways from this week in Rheumatology:

First, in treatment-refractory connective tissue diseases, B-cell maturation antigen-targeted bispecific antibodies like teclistamab offer impressive clinical response rates, but require rigorous patient selection and monitoring due to high risks of severe infection and cardiotoxicity [9].

Second, when treating anti-MDA5 positive dermatomyositis, clinicians can use a combination of advanced age, male sex, skin ulcers, elevated ferritin, lactate dehydrogenase, and low lymphocytes or CD3-positive CD4-positive T-cells to risk-stratify patients for rapidly progressive interstitial lung disease [1].

Third, upadacitinib demonstrates significantly longer real-world drug persistence than tumor necrosis factor inhibitors in rheumatoid arthritis, though both options achieve similar rates of low disease activity and remission at one year [2].

Fourth, persistent pain in early rheumatoid arthritis is frequently driven by non-inflammatory factors, with female sex, worse baseline patient-reported outcomes, and a high ratio of tender-to-swollen joints predicting unacceptable pain even when systemic inflammation is fully controlled [8].

Fifth, clinical examination of enthesitis in early peripheral spondyloarthritis is prone to overestimation, making objective ultrasound features like entheseal thickening and Power Doppler signal valuable tools for accurate diagnosis and monitoring [4].

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.